Author: admin

  • South Korean banks take the lead to bridge gender inequalities

    South Korean banks take the lead to bridge gender inequalities

    MJ Song, a South Korean working mother with a four-year-old son, considers herself lucky because she has been able to work for one company for more than 15 years without her career being hindered by starting a family.

    Her employer, a unit of Shinhan Financial Group, offers generous pay and benefits such as baby bonuses, childcare allowances and flexible working, allowing her to balance work and family life in a country notorious for long working hours and rigid corporate cultures.

    Song took two years of maternity leave after her son was born then worked for four hours a day for a year, receiving half her normal salary. Shinhan also allows women to work two hours fewer a day during pregnancy and employees with children in their first two years of primary school to start work an hour later.

    “I am satisfied with my job as the salary is high with a lot of benefits for working moms,” says Song. “The workload is heavy, but my PC gets automatically turned off after 6pm. It has been relatively easy to balance work and family life, while most of my friends have quit their jobs after childbirth.”

    Korean financial groups have been one of the most coveted workplaces among female graduates, thanks to their competitive pay and childcare-related perks, despite technology causing wider cuts to the industry’s workforce.

    Financial groups are also notable for their relatively high number of female workers in the male-dominated, manufacturing-driven economy. Female workers account for more than half of the financial sector workforce, about double the average in South Korea’s 500 biggest companies by sales, according to research group Leaders Index.

    Labour expert Bae Kyu-shik says: “Financial companies have become good employers for women, thanks to their high pay and strong internal welfare benefits.”

    Some content could not load. Check your internet connection or browser settings.

    Women boast an average 14.5 years of service at Korean banks versus men’s 15.4 years, while women’s annual salaries average Won96.9mn ($66,100), compared with Won128.4mn for men, Leaders Index data shows. Similar to the manufacturing sector, most Korean bank staff retire in their mid-fifties, but they usually receive generous severance pay and packages that amount to several years’ salary if they retire early.

    Foreign lenders in Korea, such as Citibank and Standard Chartered, also offer flexible work for parents with young children, reduced hours for pregnant women and longer paternity leave. They also offer baby bonuses, although these are less generous than those from local counterparts.

    As the country addresses the world’s lowest fertility rate of 0.75 per cent, Korean banks have been at the forefront of the government-led initiative to solve it by offering various childcare benefits. The demographic crisis poses a huge challenge for sustaining economic growth and providing pensions and healthcare for an ageing population.

    But economic and cultural discrimination means many Korean women remain reluctant to marry and have children. South Korea has the highest gender pay gap among rich countries, with women paid almost a third less than men, despite their above-average level of tertiary education, reports the OECD.

    South Korea’s male-oriented corporate culture and working hours — some of the longest in the OECD — remain a barrier to women’s labour participation, with more than 15 per cent of married women quitting jobs after having children, according to government data, while those who keep working struggle to progress in their careers.

    The government has been spending heavily to counter the low birth rate, with financial groups going beyond national requirements by offering baby bonuses worth tens of thousands of dollars and up to three years of maternity leave, as well as flexible working for parents with children aged below 10 at school. Statutory leave is up to a year and a half.

    Banks such as KB Kookmin and Woori last year started offering up to three years of “parental resignation” programmes for employees with children aged below seven, on top of a two-year childcare leave, with the guarantee of returning to the same position.

    There are limits, however. Despite the government policy to support paternity leave — a father with a child under eight can take up to a year and a half off — men taking the leave remains at a single-digit rate at most banks because of social norms that still regard childcare and household duties as a woman’s job.

    Some content could not load. Check your internet connection or browser settings.

    Despite the high proportion of female workers, few are at executive level in the financial sector, as most women work in retail banking, rather than higher-margin businesses such as corporate and investment banking, which are seen as better for promotions.

    “There are equal opportunities for hiring, but they are not equal positions,” says Park Ju-geun, head of Leaders Index, noting there is still a 30 per cent pay gap in banking. “Women still don’t have many opportunities for promotions as they are barred from key operations like strategic planning, sales, marketing and treasury departments.”

    The number of female executives is increasing after legislation in 2022 banned single-gender boards at companies with assets of more than Won2tn. But women still hold only 12.7 per cent of executive positions at South Korean banks, although this is higher than the 8.1 per cent average across the country’s 500 biggest companies, according to Leaders Index.

    There are signs of improvement, however. Internet-only lender Toss Bank and the South Korean unit of Citibank both have female chief executives, while some banks offer leadership and mentoring programmes for women.

    “Women are often hired for supplementary positions, so most fail to move up the ladder,” says Oh Hee-jung, deputy head of the Korean Finance & Service Workers’ Union. “Like in other sectors, the glass ceiling still exists in the financial sector, with most women struggling to shatter it.”

    Continue Reading

  • Pinprick blood test could detect disease 10 years before symptoms appear, study finds | Medical research

    Pinprick blood test could detect disease 10 years before symptoms appear, study finds | Medical research

    The world’s largest study into key substances in the bloodstream has paved the way for a swathe of pinprick tests that can detect early signs of disease more than a decade before symptoms appear, researchers say.

    Work on the tests follows the…

    Continue Reading

  • Chinese manufacturers’ shift to flexibility leaves gig labourers exposed

    Chinese manufacturers’ shift to flexibility leaves gig labourers exposed

    Every morning, Zhou sifts his way through the crowds of hopeful workers, factory owners and snake oil sellers that throng the open air labour market in Datang, Guangzhou in the hope of finding suitable work.

    Wading into a crowd of hopefuls surrounding a clothing factory manager perched on a bicycle one day last month, he picks up the half-finished lace top on display, weighs it in his hands and shakes his head: the pay per item is too low for a work that intricate.

    Zhou, who declined to give a full name, is one of at least 200mn people in China working in the “gig economy”, a growing, informal sector of the labour market that spans everything from delivery drivers to construction workers. And while China’s fast fashion industry has long relied on nimble day labourers like Zhou, analysts say the increasing use of short-term labour in manufacturing is harming the country’s human capital and putting workers at risk.

    “We’re a new generation of workers with a new generation of thinking,” says Zhou, a wiry and moustachioed worker in his 30s who moved to the garment production hub of Guangzhou eight years ago from the central province of Hubei. Although more flexible, he ends up working 12 hours a day, often seven days a week. “We wake up, work, finish work, sleep: it’s a two-point line.”

    Officially, Chinese companies are only supposed to employ a maximum 10 per cent of their staff on a short-term basis. But analysts say that in recent years, the proportion of temporary workers in the manufacturing sector has crept up, making life more precarious for a huge swath of the workforce and undermining labourers’ ability to learn new skills.

    Textile workshop in Datang. Analysts say that in recent years, the proportion of short-term workers in the manufacturing sector has crept up © Qilai Shen/Bloomberg

    For instance, a study by Peking University academic Zhang Dandan estimated that there were approximately 40mn short-term workers in the manufacturing sector by 2024, or about 31 per cent of the total. Previous surveys from five provinces suggested that the proportion of flexible workers was 20 per cent in 2017, after exhibiting a “significant upward trend” in the previous seven years, she wrote.

    Many Chinese factory workers are employed in long-term, full-time roles and sometimes remain at individual factories for decades. Under such conditions, they are entitled to workplace and health insurance, protection from unfair dismissal, a degree of training and, after a certain period of service, retirement and other benefits.

    Hiring temporary workers, either through contract labour agencies or via open air markets such as the one in Datang, can give factory managers more flexibility and lower costs by reducing payments for training and other benefits. For workers, it can mean greater choice over where to work and, in the short term, higher pay, as many receive bonuses for completing stints at each plant.

    But it also leaves them exposed. Most day workers and many agency labourers do not have contracts or workplace insurance and are clustered in the most low-skilled part of the production process, such as the final assembly of electronics.

    Analysts warn that the funnelling of large numbers of workers into tedious jobs that offer little chance of training or career advancement could create a skills deficit in the future and impede social mobility.

    “Contract labour becomes this very convenient way of just having this flexibility without the risk of any long-term commitments, without the risks of paying compensation, or the difficulties of firing people,” says Dmitri Kessler, founder of the Economic Rights Institute.

    Kessler says that using short-term labourers in electronics manufacturing also allows factories quickly to replace workers hurt when performing physically arduous tasks or exposed to harmful activities. “From our perspective, it’s extremely problematic,” he says.

    31%

    Estimated share of short-term workers in manufacturing sector by 2024

    Moreover, because hourly wages for temporary roles are often higher than for fixed work — though still cost the employer less given reduced additional benefits — many workers end up opting for short-term roles with little prospect of advancement and do not care about the companies they work for.

    “You develop a kind of a dependence on the most base level of employment . . . that has an impact on the productivity of the workers themselves,” says Kessler.

    Jenny Chan, a sociologist at the Hong Kong Polytechnic University, says that some factories can employ as many as 70 per cent of their workers on a temporary basis during peak seasons, although an absolute number is difficult to pin down. “This is definitely a more precarious, very fluid form of labour,” she says.

    The proportion of workers employed on a temporary basis has increased since about 2008, following both the global financial crisis and China’s introduction of a stricter labour law that offers greater protections to full-time workers, she says.

    As the growing usage started to attract greater government scrutiny, some factories turned to the country’s network of vocational schools to send trainees or interns to meet their staffing needs. Renewed scrutiny of the use of vulnerable student workers has only pushed the practice underground, she says. “They have been continuing the practice . . . they just made it more difficult to identify.”

    Mo, a temporary garment factory worker in his 30s who declined to give a full name, says he went through a variety of short-term roles in the services sector before arriving in the Datang garment manufacturing district to find work.

    Nowadays, he adds, outside of the most skilled jobs, lots of employment in China is offered on a flexible basis.

    “You just make yourself OK from one day to the next. But if you want to get married, have a family, you definitely can’t think like this,” Mo says of his life as a day labourer while he peruses yellow posters advertising roles in Datang. “Doing this kind of work is a rotten state of affairs.”

    Continue Reading

  • About half of UK novelists fear AI will take their work entirely – study

    About half of UK novelists fear AI will take their work entirely – study

    About half of published novelists in the UK fear that artificial intelligence will replace their work entirely, a report has suggested.

    Cambridge University researchers surveyed 258 published novelists, 32 literary agents and 42…

    Continue Reading

  • India aims to train vast pool of poorly skilled workers

    India aims to train vast pool of poorly skilled workers

    In a factory complex in Noida, an industrial hub outside New Delhi, Vinod Sharma, the managing director of an Indian electronic component maker, is trying to improve the skills of a small part of India’s vast but poorly trained workforce.

    “We teach people from zero,” says Sharma at Deki Electronics, which supplies capacitors to an array of industries in Asia, Europe and the Middle East.

    Even day-to-day life in the workplace has to be taught, he says. “We have to go to the extent of teaching them how to walk on the stairs, how to walk in the corridor, because they have never been in a building like this,” says Sharma.

    With Prime Minister Narendra Modi focused on boosting Swadeshi — locally made products — as punitive US tariffs squeeze export industries and threaten to put a damper on the world’s fastest-growing large economy, the opportunities for India’s workforce of more than 600mn have rarely been greater.

    Yet government officials and leaders in industries from services to manufacturing to energy lament a critical shortfall of practical training, digital literacy and soft skills.

    Some content could not load. Check your internet connection or browser settings.

    Modi has said that “skill development and employment are crucial needs in India”, at a time when he is luring in multinationals such as Apple, as he seeks to establish India as a manufacturing and services hub to rival the likes of China.

    The UN’s most recent estimates from June have put the country’s population at 1.46bn, comfortably ahead of China’s 1.41bn, with nearly 68 per cent of Indians falling within the working age group of 15 to 64.

    But only 4.4 per cent of its workforce aged 15 to 29 is formally skilled, according to India’s finance ministry, while the skill development ministry acknowledged that only just over half of India’s graduates have the “skills needed by a modern economy”.

    This is “significantly lower than other large Asian economies”, noted a World Bank report last year, adding that “although India’s education system is of high quality, the supply of skilled labour is mediocre”.

    300mn

    Farm and non-farm workers in need of more training

    According to the International Labour Organization, India’s “industry involvement in training is still low” with only 36 per cent of companies participating in upskilling programmes, against 85 per cent in China, 52 per cent in Russia, and 51 per cent in Brazil.

    This year Modi kicked off several training and internship schemes, including a flagship government project with India’s top 500 public and private companies — including Jindal, Reliance and Tata — aimed at addressing the yawning skills gap. It has a five-year goal of placing 10mn young workers in industries including energy, automotive, food and banking.

    Anil Bahuguna, chief of skill development at state-run energy company ONGC, which is participating in one of the government’s programmes, says that when it comes to oil and gas, the available labour force has “low technical exposure to field machinery and this adversely impacts the time and cost of a project”.

    As India “navigates rapid technological and economic change, skills gaps, cited by 65 per cent of organisations as a major barrier, threaten to slow progress”, the government said when it rolled out “India Skills Accelerator” this year, the latest in a string of training programmes aimed at boosting employability.

    These programmes form part of a drive to move away from India’s traditional placement landscape where workers used to get basic training through jobs in small and medium-sized enterprises.

    Some content could not load. Check your internet connection or browser settings.

    “India’s skilling infrastructure has always been very, very small,” says Pronab Sen, an economist and former principal economic adviser to India’s Planning Commission, adding that as the economy expands and grows more sophisticated, “we need to meet the demands of the organised sector, the big companies”.

    Abhinav Baliyan, managing director of Educator Extraordinaire, a company that runs vocational training centres in Jharkhand, says India has been unable to cash in fully on its “demographic dividend” of a vast growing working-age population.

    This is partly because of a poorly skilled workforce. Four-in-five employers have reported difficulty finding the skilled talent they need in 2025, says recruiter Manpower, more than the global average, even as India has a higher demand for workers with IT and data skills than in China and Singapore.

    While the Confederation of Indian Industry estimates that 10mn to 12mn young people enter the labour market annually, some 300mn farm and non-farm workers are already in need of being skilled, reskilled or upskilled to “achieve higher productivity”, says Manish Sabharwal of recruitment company Teamlease.

    But the growing population could also put further pressure on fast-skilling the workforce. For Sourav Roy, chief of corporate social responsibility at Tata Steel, “there are more people that need skills than what we can actually offer in general” in India.

    Rituparna Chakraborty, a board member at the Goa Institute of Management, says: “I don’t think we’ll ever have enough skilled people because India is in a position where more and more jobs will come dragging more people into the workforce, which means skilled workforce demand will keep on going up.”

    Online skilling platform upGrad’s chair Ronnie Screwvala says that at the moment, India has a large pool of well-trained engineers and graduate-level workers in technology and computer sciences, but not enough focus has been put on practical skills. Indians now need training that “can offer immediate relevance”.

    That much is clear to Ayush Tiwari, a graduate in biotechnology and beneficiary of the latest government programme. He is now an intern at the waste management unit of listed chemical company DCM Shriram in the state of Uttar Pradesh: “In the past six months, I have learned practically what I yearned for when I was studying.”

    Back in Noida, 18-year-old Sachin Kumar, who travelled 700km to take a placement at what Deki calls its “Garden of Knowledge” training centre, is one beneficiary of India’s latest push on skills development. “I am not just learning to be a machine operator, but pretty much how to do anything at all,” he says.

    Continue Reading

  • Galaxy Watch Series Health Features Help Save Lives – Samsung Global Newsroom

    Galaxy Watch Series Health Features Help Save Lives – Samsung Global Newsroom

    “I could have collapsed at any moment.”

    That’s how Roberto Gallart describes his health on the pivotal day his Galaxy Watch6 alerted him to a life-threatening heart condition. A single notification prompted him to seek…

    Continue Reading

  • Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

    SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met the primary endpoints and all key secondary endpoints. Innovent plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the near term.

    GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI ≥30 kg/m²). The study enrolled 462 participants (including 16% with type 2 diabetes), randomized in a 2:1 ratio to receive mazdutide 9 mg group or placebo in the 60-week double-blind treatment period (mean baseline weight: 94.0 kg; mean BMI: 34.3 kg/m²).

    During the treatment period, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed in Week 60. At Week 60, the mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9 mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group (P<0.0001 for all comparisons). The key secondary endpoints demonstrated that among participants without type 2 diabetes, the mazdutide 9 mg group showed a mean weight reduction of 20.08% at Week 60 (placebo: 2.81%), with 48.7% of participants achieving a weight reduction of 20% or more (placebo: 3.1%; P<0.0001).

    Furthermore, all key secondary endpoints of the study were met, including other body weight endpoints, waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and serum uric acid levels. Mazdutide 9 mg demonstrated superiority to placebo in all the above weight-loss and cardiometabolic endpoints.

    This study also evaluated liver fat content using MRI-PDFF in a subset of participants. Among participants (without type 2 diabetes) with baseline liver fat content ≥10%, the mean percent change in liver fat content from baseline to week 60 was -71.9% in the mazdutide 9 mg group compared with 5.1% in the placebo group.

    Mazdutide 9 mg demonstrated favorable tolerability and safety profiles, with no new safety signals identified. The majority of gastrointestinal adverse events were mild to moderate in severity and transient in nature. The proportion of participants who discontinued treatment prematurely due to adverse events was 2.9% in the mazdutide 9 mg group and 0% in the placebo group.

    Professor Linong Ji, the leading principal investigator of the study, Peking University People’s Hospital, stated, “As a chronic disease with a complex etiology, obesity requires public awareness of long-term treatment and management. China faces a high prevalence of obesity, with obese individuals bearing a significant burden of cardiometabolic diseases. Those with a BMI exceeding 32.5 kg/m², often experience an even greater cardiometabolic burden. This patient population requires special attention in clinical weight management and metabolic syndrome prevention. According to current Chinese clinical guidelines, metabolic surgery is often considered a first-line treatment for such patients. Extensive clinical evidence on GLP-1 receptor agonists demonstrates that the weight-loss efficacy of these drugs is dose-dependent. Therefore, developing pharmacological treatments tailored to moderate-to-severe obesity could offer new therapeutic options for this group. The investigators of this study and I are delighted that this study met both its primary endpoints and all key secondary endpoints. Mazdutide 9 mg has once again demonstrated outstanding weight-loss efficacy, multiple metabolic benefits and favorable safety. We hope mazdutide 9 mg will successfully achieve regulatory approval, supporting stratified weight management for China’s obese population and enabling more personalized treatment approaches.”

    Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent, stated, “Mazdutide 9 mg is currently the only GLP-1 receptor agonist that achieves over 20% weight loss in obese adults without T2D after 1 year of treatment with just a 2-step dose titration. Its development provides evidence-based medical support for effective weight management in Chinese patients with moderate-to-severe obesity, offering an alternative to metabolic surgery. We plan to submit a supplemental application for mazdutide 9 mg in the near future, aiming to deliver this innovative treatment to patients as soon as possible. Concurrently, the lifecycle management plan for mazdutide continues to expand its boundaries, exploring further therapeutic potentials. We are developing mazdutide for other indications on the basis of scientific evidence and unmet medical needs. Innovent will continue to strategically build our next-generation product pipeline in the cardiovascular and metabolic (CVM) field, and help people’s pursuit of a healthy life.”

    Mazdutide has earned widespread recognition supported by robust data set. Its Phase 2 clinical trial in Chinese subjects with overweight or obesity was selected by Nature Communications as one of the 50 most important studies in translational and clinical research and highlighted as Editor’s Choice. Additionally, mazdutide was listed among the “Top 10 Most Anticipated Drug Launches of 2025” by the FIERCE Pharma.

    Furthermore, clinical findings on mazdutide have been featured in top-tier international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, as well as presented at leading scientific conferences including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) annual meetings. Notably, mazdutide is the first innovative drug in China’s endocrinology and metabolism field to have clinical results published in The New England Journal of Medicine, underscoring its significant clinical value.

    About Mazdutide

    Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG/GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.

    Innovent has currently conducted or completed seven Phase 3 clinical studies of mazdutide, including:

    • GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;
    • GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;
    • DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;
    • DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;
    • DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;
    • GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide 2.4mg in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);
    • GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;

    Among these, the first five Phase 3 clinical studies have all met their primary endpoints, while the remaining two Phase 3 studies are still ongoing.

    In addition, several clinical studies of mazdutide are ongoing in adolescents with obesity, patients with metabolic dysfunction-associated steatohepatitis (MASH),heart failure with preserved ejection fraction (HFpEF) etc.

    Mazdutide has received NMPA approval for two indications:

    First Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

    • BMI ≥ 28 kg/m² (obesity); or
    • BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome).

    Second Indication: For glycemic control in adults with type 2 diabetes.

    Monotherapy:

    For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.

    Combination Therapy:

    For adults with T2D who still have poor glycemic control despite:

    • Diet and exercise, plus Metformin and/or sulfonylureas;
    • Diet and exercise, plus Metformin and/or SGLT2 inhibitors (SGLT2i).

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-looking statement

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • New study shows how microbial transmission can affect adaptive behavior

    New study shows how microbial transmission can affect adaptive behavior

    Most of us are familiar with natural selection — the process where organisms with traits better suited to their environment are more likely to survive and reproduce, passing those traits to their offspring. As a result, the genes and…

    Continue Reading

  • Local chikungunya cases top 800 in 2025

    Local chikungunya cases top 800 in 2025

    French health authorities, in an update today, report a total of 804 locally acquired chikungunya cases year to date.

    • 787 cases of chikungunya spread across 82 clusters (1 to 141 cases per cluster; 73 of these clusters are closed), and

    • 17 isolated…

    Continue Reading

  • Snapdragon Control Panel for gaming is now available

    Snapdragon Control Panel for gaming is now available

    Back in May 2025, Qualcomm released the Adreno Control Panel into beta for developers, a graphics utility software specifically designed for Snapdragon X Elite devices as a way to optimize game performance.

    Now, several months later, Qualcomm has…

    Continue Reading